1. Epidemiology of severe sepsis in the United States;Angus;Crit Care Med,2001
2. Efficacy and safety of recombinant human activated protein C for severe sepsis;Bernard;N Engl J Med,2001
3. US Food and Drug Administration. Drotrecogin alfa (activated) (recombinant human activated protein C [rhAPC]), Xigris, BLA No. 125029/0. FDA briefing information. August 6, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_01_Sponsor.htm. Accessed November 4, 2002
4. US Food and Drug Administration. Drotrecogin alfa (activated) (recombinant human activated protein C [rhAPC]), Xigris, BLA No. 125029/0. FDA briefing information. September 12, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3787b1.htm. Accessed November 4, 2002
5. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis;Greenman;JAMA,1991